iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/31218911/
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Nov;25(13):1728-1735.
doi: 10.1177/1352458519843051. Epub 2019 Jun 20.

Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

Melissa Cambron  1 , Jop Mostert  2 , Marie D'Hooghe  3 , Guy Nagels  3 , Barbara Willekens  4 , Jan Debruyne  5 , Luc Algoed  6 , Wim Verhagen  7 , Raymond Hupperts  8 , Dorothea Heersema  9 , Jacques De Keyser  10 ; FLUOX-PMS Study Group
Collaborators, Affiliations
Editorial

Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

Melissa Cambron et al. Mult Scler. 2019 Nov.

Abstract

Background: Preclinical studies suggest that fluoxetine has neuroprotective properties that might reduce axonal degeneration in multiple sclerosis (MS).

Objective: To determine whether fluoxetine slows accumulation of disability in progressive MS.

Methods: In a double-blind multicenter phase 2 trial, patients with primary or secondary progressive MS were randomized to fluoxetine 40 mg/day or placebo for a period of 108 weeks. Clinical assessments were performed every 12 weeks by trained study nurses who visited the patients at their home. The primary outcome was the time to a 12-week confirmed 20% increase in the Timed 25 Foot Walk or 9-Hole Peg test. Secondary outcomes included the Hauser ambulation index, cognitive tests, fatigue, and brain magnetic resonance imaging (MRI).

Results: In the efficacy analysis, 69 patients received fluoxetine and 68 patients received placebo. Using the log-rank test (p = 0.258) and Cox regression analysis (p = 0.253), we found no significant difference in the primary outcome between the two groups. Due to an unexpected slow rate of progression in the placebo group, there was insufficient statistical power to detect a potential benefit of fluoxetine. We found no differences between the two groups for secondary outcomes.

Conclusion: The trial failed to demonstrate a neuroprotective effect of fluoxetine in patients with progressive MS.

Keywords: Multiple sclerosis; clinical trial; fluoxetine; neuroprotection; outcome; progressive multiple sclerosis.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources